These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 377165)

  • 1. Tamoxifen-induced regression of benign breast lesions.
    Ricciardi I; Ianniruberto A
    Obstet Gynecol; 1979 Jul; 54(1):80-4. PubMed ID: 377165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women.
    Sherman BM; Chapler FK; Crickard K; Wycoff D
    J Clin Invest; 1979 Aug; 64(2):398-404. PubMed ID: 110834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine for treatment of benign breast disease. A double-blind clinical trial versus placebo.
    Parlati E; Polinari U; Salvi G; Giorlandino C; Liberale I; Fiorella G; Dell'Acqua S
    Acta Obstet Gynecol Scand; 1987; 66(6):483-8. PubMed ID: 3321867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Action of tamoxifen on folliculogenesis in the menstrual cycle of infertile patients.
    Fukushima T; Maeyama M
    Fertil Steril; 1983 Aug; 40(2):210-4. PubMed ID: 6409673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin response to thyrotropin-releasing hormone as a guideline for cyclical mastalgia treatment.
    Rea N; Bove F; Gentile A; Parmeggiani U
    Minerva Med; 1997 Nov; 88(11):479-87. PubMed ID: 9433398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent.
    Jordan VC; Fritz NF; Langan-Fahey S; Thompson M; Tormey DC
    J Natl Cancer Inst; 1991 Oct; 83(20):1488-91. PubMed ID: 1920495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer.
    Számel I; Vincze B; Hindy I; Hermann I; Borvendég J; Eckhardt S
    Oncology; 1986; 43(1):7-11. PubMed ID: 3079899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol.
    Colin C; Gaspard U; Lambotte R
    Arch Gynakol; 1978 Feb; 225(1):7-13. PubMed ID: 345994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of anti-estrogen therapy in metastatic breast cancer (preliminary results). Part II].
    Firusian N; Schmidt CG
    Med Welt; 1977 Dec; 28(51-52):2065-7. PubMed ID: 414049
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women.
    Groom GV; Griffiths K
    J Endocrinol; 1976 Sep; 70(3):421-8. PubMed ID: 978103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of changes in serum estradiol and progesterone during the menstrual cycle to the thyrotropin and prolactin responses to thyrotropin-releasing hormone.
    Sawin CT; Hershman JM; Boyd AE; Longcope C; Bacharach P
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1296-302. PubMed ID: 122427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course.
    Willis KJ; London DR; Ward HW; Butt WR; Lynch SS; Rudd BT
    Br Med J; 1977 Feb; 1(6058):425-8. PubMed ID: 837137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of danazol treatment of women with fibrocystic disease of breast].
    Baranowska B; Stopińska-Głuszak U
    Pol Tyg Lek; 1989 Aug 7-14; 44(32-33):771-3. PubMed ID: 2701752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of breast pain.
    Faiz O; Fentiman IS
    Int J Clin Pract; 2000 May; 54(4):228-32. PubMed ID: 10912311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of treatment with tamoxifen on serum levels of various steroid and protein hormones in women with breast cancer].
    Grodecka-Gazdecka S; Kociałkowski K; Chwalisz K; Baron J
    Endokrynol Pol; 1985; 36(6):341-8. PubMed ID: 3833535
    [No Abstract]   [Full Text] [Related]  

  • 17. [Mammography and echography in the diagnosis of expansive lesions in the dysplastic breast].
    Gozzi G; Polonio G; Cressa C; de Morpurgo P
    Radiol Med; 1984 May; 70(5):313-8. PubMed ID: 6397780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiestrogen-induced remissions in stage IV breast cancer.
    Manni A; Trujillo J; Marshall JS; Pearson OH
    Cancer Treat Rep; 1976 Oct; 60(10):1445-50. PubMed ID: 1021225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experience with danazol treatment of endometriosis and mastopathy].
    Pavelka R; Schneider WH
    Wien Klin Wochenschr; 1981 Oct; 93(19):595-9. PubMed ID: 6798763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term tamoxifen treatment in benign breast diseases.
    Cupceancu B
    Endocrinologie; 1985; 23(3):169-77. PubMed ID: 4048817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.